Skip to content
DataLookout
Menu

EMPA-BDNCT07472920

Empagliflozin Adjunctive Therapy in Bipolar Depression

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 10 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Aug 2027 Show 5 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Mar 9, 2026 to Nov 12, 2026
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in depressive symptom severity (MADRS total score)
Timeframe: Baseline and 12 weeks after treatment initiation

Secondary (2)

Change in insulin resistance (HOMA-IR)
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

Arms and interventions

Empagliflozin Adjunctive Therapy in Bipolar DepressionExperimental

Participants will receive empagliflozin orally once daily as an adjunct to their usual psychiatric treatment. The dose will start at 10 mg/day for the first 2 weeks and increase to 25 mg/day for the following 10 weeks, totaling a 12-week intervention period. The study will evaluate changes in depressive symptoms, insulin resistance, and metabolic parameters in adults with bipolar depression and insulin resistance. All participants will continue their standard psychiatric medications under medical supervision throughout the study.

Drugs: Empagliflozin (EMPA)

Sites

1 site in 1 country

  • Institute of Psychiatry, University of São Paulo Medical School (IPq-FMUSP)São Paulo, São Paulo, Brazil